Uskudar University, Department of Psychiatry, Istanbul, Turkey; NP Brain Hospital, İstanbul, Turkey.
Uskudar University, Department of Psychiatry, Istanbul, Turkey; NP Brain Hospital, İstanbul, Turkey.
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110138. doi: 10.1016/j.pnpbp.2020.110138. Epub 2020 Oct 16.
The human body can be considered a superorganism in which it's eukaryotic cells and prokaryotic microorganisms coexist. Almost every organ system of the body lives a symbiotic life with these commensal bacteria. Intestinal microbiota has an important role in shaping, organizing and maintaining mental functions from as early as the intrauterine period. Microbiota-based approaches are becoming more prominent in understanding and treating the etiopathogenesis of neuropsychiatric disorders, especially depression. Antidepressant drugs, which are the first-line option in the treatment of depression today, also contain antimicrobial and immunomodulatory mechanisms of action. Treatment options for directly modifying the microbiota composition include prebiotics, probiotics (psychobiotics) and fecal microbiota transplantation. There are few preclinical and clinical studies on the efficacy and reliability of these treatment options in depression. This article will review pertinent studies on the role of intestinal microbiota in depression and discuss the treatment potential of altering ones gut microbiome.
人体可以被视为一个超生物体，其中真核细胞和原核微生物共存。人体的几乎每个器官系统都与这些共生细菌共生。肠道微生物群在塑造、组织和维持从宫内期开始的精神功能方面具有重要作用。基于微生物群的方法在理解和治疗神经精神疾病（尤其是抑郁症）的病因发病机制方面变得越来越突出。抗抑郁药是当今治疗抑郁症的首选药物，它们也具有抗微生物和免疫调节作用机制。直接改变微生物群落组成的治疗选择包括益生元、益生菌（心理益生菌）和粪便微生物群移植。关于这些治疗选择在抑郁症中的疗效和可靠性的临床前和临床研究很少。本文将回顾有关肠道微生物群在抑郁症中的作用的相关研究，并讨论改变肠道微生物组的治疗潜力。
